Evidence map›Paper›PMID 25255082›Full record

ArticlePLoS computational biology2014

A Bayesian framework to identify methylcytosines from high-throughput bisulfite sequencing data.

Qing Xie, Qi Liu, Fengbiao Mao, Wanshi Cai, Honghu Wu, Mingcong You, Zhen Wang, Bingyu Chen, Zhong Sheng Sun, Jinyu Wu

Abstract read
In one paragraph

Article in PLoS computational biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qing XieInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.
Qi LiuInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.
Fengbiao MaoBeijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Wanshi CaiBeijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Honghu WuInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.
Mingcong YouInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.
Zhen WangInstitute of Molecular Medicine, Department of blood transfusion, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Bingyu ChenInstitute of Molecular Medicine, Department of blood transfusion, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Zhong Sheng SunInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China; Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Jinyu WuInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput bisulfite sequencing technologies have provided a comprehensive and well-fitted way to investigate DNA methylation at single-base resolution. However, there are substantial bioinformatic challenges to distinguish precisely methylcytosines from unconverted cytosines based on bisulfite sequencing data. The challenges arise, at least in part, from cell heterozygosis caused by multicellular sequencing and the still limited number of statistical methods that are available for methylcytosine calling based on bisulfite sequencing data. Here, we present an algorithm, termed Bycom, a new Bayesian model that can perform methylcytosine calling with high accuracy. Bycom considers cell heterozygosis along with sequencing errors and bisulfite conversion efficiency to improve calling accuracy. Bycom performance was compared with the performance of Lister, the method most widely used to identify methylcytosines from bisulfite sequencing data. The results showed that the performance of Bycom was better than that of Lister for data with high methylation levels. Bycom also showed higher sensitivity and specificity for low methylation level samples (<1%) than Lister. A validation experiment based on reduced representation bisulfite sequencing data suggested that Bycom had a false positive rate of about 4% while maintaining an accuracy of close to 94%. This study demonstrated that Bycom had a low false calling rate at any methylation level and accurate methylcytosine calling at high methylation levels. Bycom will contribute significantly to studies aimed at recalibrating the methylation level of genomic regions based on the presence of methylcytosines.

Indexed as

Algorithms5-MethylcytosineBayes TheoremHigh-Throughput Nucleotide SequencingHumansModels, GeneticSensitivity and SpecificitySequence Analysis, DNASulfites5-Methylcytosinehydrogen sulfiteSulfites

Identifiers

PMID25255082
PMCPMC4177668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.